CannaPharmaRX reports director resignation, updates plan

CannaPharmaRX, Inc. reported that director Rick Orman resigned from its Board of Directors effective immediately on January 8, 2026.

Rhea-AI Filing Summary

CannaPharmaRX, Inc. reported that director Rick Orman resigned from its Board of Directors effective immediately on January 8, 2026. The company states that his resignation did not result from any dispute or disagreement with the company or the Board regarding operations, policies, or practices.

The company also noted that on January 12, 2026, it issued a press release providing corporate updates and outlining its 2026 growth strategy, which has been furnished as an exhibit to this report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did CannaPharmaRX (CPMD) disclose in this 8-K?

CannaPharmaRX, Inc. disclosed that director Rick Orman resigned from the Board of Directors effective immediately on January 8, 2026.

Did Rick Orman resign from CannaPharmaRX due to a disagreement with the company?

The company states that Mr. Orman’s resignation did not indicate it was the result of any dispute or disagreement with CannaPharmaRX or its Board on operations, policies, or practices.

What additional information did CannaPharmaRX (CPMD) provide about its 2026 plans?

On January 12, 2026, CannaPharmaRX issued a press release providing corporate updates and its 2026 growth strategy, which is furnished as an exhibit.

Which exhibit covers the CannaPharmaRX 2026 growth strategy press release?

The press release dated January 12, 2026 that discusses corporate updates and the 2026 growth strategy is furnished as Exhibit 99.2.

Who signed the CannaPharmaRX (CPMD) Form 8-K?

The Form 8-K was signed on behalf of CannaPharmaRX, Inc. by Constantine Nkafu, the company’s Chief Executive Officer.

Is CannaPharmaRX currently listed on a national securities exchange?

The filing’s securities table lists the title of each class and related trading symbols as N/A, indicating no class registered under Section 12(b) on a national exchange in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:02 PM Learn about SEC filing dates

0001081938false00010819382026-01-082026-01-08iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 ___________________________

FORM 8-K

 ___________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2026

 ___________________________

CannaPharmaRX, Inc.

(Exact name of registrant as specified in its charter)

 ___________________________

Delaware		333-251016		27-4635140
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4439 Township Rd 304

Mountain View County, Alberta, Canada T0M 0R0

(Address of principal executive offices, including zip code)

(403) 637-0420

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers. 

Departure of Director

On January 8, Rick Orman informed the Board of Directors (the “Board”) of CannaPharmaRx, Inc. (the “Company”) of his resignation as a member of the Board effective immediately.

Mr. Orman’s resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company

Item 8.01 Regulation FD Disclosure.

On January 12, 2026, the Company issued a press release providing corporate updates and 2026 growth strategy. A copy of the press release is furnished as Exhibit 99.2 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Resignation letter from Rick Orman
99.2		Press Release dated January 12, 2026

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CANNAPHARMARX, INC.
January 12, 2026	By:	/s/ Constantine Nkafu
	Name:	Constantine Nkafu
	Title:	Chief Executive Officer

3